Sanofi (France)
NEWS
Here’s a look at what’s on the U.S. Food and Drug Administration’s schedule for the next two weeks.
The two companies will evaluate a smartphone-based self-testing solution for COVID-19, using Luminostics’ innovative technology and Sanofi’s clinical research abilities.
It’s likely that more companies and universities will add additional assets as time goes on.
The two companies are eying the second half of this year to begin clinical trials on their combined project and, if the vaccine meets expectations, the companies said it could be available for use in the second half of 2021.
Many people have lost their jobs and, as a result, their insurance. That can be daunting enough, but for those who need life-saving drugs such as insulin, the situation is magnified.
While the world is working to slow the COVID-19 pandemic by social isolation and quarantine, numerous companies globally are working to develop a vaccine against the virus.
This Clinical Catch-Up has been split into three sections: COVID-19-Related Clinical Trials; Non-COVID-19-Related Clinical Trials; and Trials Affected by the COVID-19 Pandemic. Here’s a look.
Biopharma companies from across the globe provide updates on their pipelines and business practices.
The companies initiated a Phase II/III trial in Italy, Spain, Germany, France, Japan, Canada and Russia.
JOBS
IN THE PRESS